vs

Side-by-side financial comparison of Granite Point Mortgage Trust Inc. (GPMT) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $29.1M, roughly 1.2× Granite Point Mortgage Trust Inc.). Granite Point Mortgage Trust Inc. runs the higher net margin — -81.9% vs -304.2%, a 222.3% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -24.9%). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 52.3%).

Granite Point Mortgage Trust Inc. is a U.S.-based real estate finance company that primarily originates, manages and invests in senior secured commercial real estate debt instruments. Its core portfolio covers loans backed by multifamily, office, industrial, retail and other commercial property types across key U.S. regional markets, serving institutional and commercial real estate operator clients.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

GPMT vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.2× larger
RXRX
$35.5M
$29.1M
GPMT
Growing faster (revenue YoY)
RXRX
RXRX
+706.7% gap
RXRX
681.7%
-24.9%
GPMT
Higher net margin
GPMT
GPMT
222.3% more per $
GPMT
-81.9%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
52.3%
GPMT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GPMT
GPMT
RXRX
RXRX
Revenue
$29.1M
$35.5M
Net Profit
$-23.8M
$-108.1M
Gross Margin
59.8%
Operating Margin
-81.9%
-304.8%
Net Margin
-81.9%
-304.2%
Revenue YoY
-24.9%
681.7%
Net Profit YoY
38.7%
39.6%
EPS (diluted)
$-0.58
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GPMT
GPMT
RXRX
RXRX
Q4 25
$29.1M
$35.5M
Q3 25
$33.7M
$5.2M
Q2 25
$33.8M
$19.2M
Q1 25
$35.1M
$14.7M
Q4 24
$38.7M
$4.5M
Q3 24
$44.3M
$26.1M
Q2 24
$48.5M
$14.4M
Q1 24
$12.5M
$13.8M
Net Profit
GPMT
GPMT
RXRX
RXRX
Q4 25
$-23.8M
$-108.1M
Q3 25
$3.0M
$-162.3M
Q2 25
$-13.4M
$-171.9M
Q1 25
$-7.0M
$-202.5M
Q4 24
$-38.8M
$-178.9M
Q3 24
$-31.0M
$-95.8M
Q2 24
$-63.1M
$-97.5M
Q1 24
$-74.1M
$-91.4M
Gross Margin
GPMT
GPMT
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
GPMT
GPMT
RXRX
RXRX
Q4 25
-81.9%
-304.8%
Q3 25
9.2%
-3327.6%
Q2 25
-39.5%
-916.8%
Q1 25
-19.8%
-1297.9%
Q4 24
-100.3%
-4042.4%
Q3 24
-70.0%
-377.1%
Q2 24
-130.1%
-697.4%
Q1 24
-591.9%
-698.4%
Net Margin
GPMT
GPMT
RXRX
RXRX
Q4 25
-81.9%
-304.2%
Q3 25
9.0%
-3135.3%
Q2 25
-39.5%
-894.2%
Q1 25
-20.0%
-1373.3%
Q4 24
-100.3%
-3935.5%
Q3 24
-70.0%
-367.5%
Q2 24
-130.1%
-676.6%
Q1 24
-591.9%
-662.4%
EPS (diluted)
GPMT
GPMT
RXRX
RXRX
Q4 25
$-0.58
$-0.17
Q3 25
$-0.01
$-0.36
Q2 25
$-0.35
$-0.41
Q1 25
$-0.22
$-0.50
Q4 24
$-0.86
$-0.56
Q3 24
$-0.69
$-0.34
Q2 24
$-1.31
$-0.40
Q1 24
$-1.53
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GPMT
GPMT
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$66.0M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$552.7M
$1.1B
Total Assets
$1.8B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GPMT
GPMT
RXRX
RXRX
Q4 25
$66.0M
$743.3M
Q3 25
$62.7M
$659.8M
Q2 25
$85.1M
$525.1M
Q1 25
$85.7M
$500.5M
Q4 24
$87.8M
$594.4M
Q3 24
$113.5M
$427.6M
Q2 24
$85.9M
$474.3M
Q1 24
$155.2M
$296.3M
Total Debt
GPMT
GPMT
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
GPMT
GPMT
RXRX
RXRX
Q4 25
$552.7M
$1.1B
Q3 25
$582.0M
$1.0B
Q2 25
$584.2M
$919.1M
Q1 25
$604.7M
$933.9M
Q4 24
$619.1M
$1.0B
Q3 24
$667.8M
$524.6M
Q2 24
$704.6M
$584.4M
Q1 24
$774.1M
$401.2M
Total Assets
GPMT
GPMT
RXRX
RXRX
Q4 25
$1.8B
$1.5B
Q3 25
$1.8B
$1.4B
Q2 25
$1.9B
$1.3B
Q1 25
$2.0B
$1.3B
Q4 24
$2.1B
$1.4B
Q3 24
$2.3B
$726.5M
Q2 24
$2.5B
$775.9M
Q1 24
$2.7B
$557.8M
Debt / Equity
GPMT
GPMT
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GPMT
GPMT
RXRX
RXRX
Operating Cash FlowLast quarter
$2.7M
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GPMT
GPMT
RXRX
RXRX
Q4 25
$2.7M
$-46.1M
Q3 25
$4.5M
$-117.4M
Q2 25
$736.0K
$-76.4M
Q1 25
$-5.7M
$-132.0M
Q4 24
$8.8M
$-115.4M
Q3 24
$6.1M
$-59.2M
Q2 24
$987.0K
$-82.2M
Q1 24
$1.7M
$-102.3M
Free Cash Flow
GPMT
GPMT
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
GPMT
GPMT
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
GPMT
GPMT
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%
Cash Conversion
GPMT
GPMT
RXRX
RXRX
Q4 25
Q3 25
1.49×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons